NovoCure Ltd
NVCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.97B
Close$
$-8.92
155.2% downside
Current Fair Value
155.2% downsideOvervalued by 155.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.97 Billion |
|---|---|
| Enterprise Value | $2.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 0.9 |
| Outstanding Shares | 114,149,838 |
Return
| Return on Equity | -52.32% |
|---|---|
| Return on Assets | -21.96% |
| Return on Invested Capital | -32.25% |
Valuation & Multiples
| P/E Ratio | -11.24 |
|---|---|
| PEG | -10.48 |
| Price to Sales | 3.23 |
| Price to Book Ratio | 8.08 |
| Enterprise Value to Revenue | 3.13 |
| Enterprise Value to EBIT | -11.48 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.71 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 30, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$167.77 M
Average shareholder expectationNext Earnings Call
Expected Date
July 23, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$172.72 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7442▲ 39.69% |
|---|---|
| Total Calls | 930,900▼ 13.15% |
| Total Puts | 692,800▲ 86.09% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.71%▲ 3.35% |
|---|---|
| Total Invested | $1.08B▼ 12.79% |
| Investors Holding | 230▼ 14.00% |
ESG Score
No data
About NovoCure Ltd
CEO: Asaf Danziger